Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and disease characteristics of the patient cohort

From: Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood

Pattern Patient no. RRMS/SPMS Sex (f/m) Age at time of relapse (yrs) Age at time of diagnosis (yrs) Relapse EDSS* Treatment at time of relapse Remission EDSS* Treatment at time of remission MS severity (percentile)
I 1 RRMS f 19 17 3.0 GA 2.0 GA 71
I 2 RRMS f 30 15 4.0 IFN 3.0 IFN 51
I 3 RRMS f 18 17 4.0 None 4.0 None 91
I 4 RRMS f 42 27 6.0 GA 4.0 GA 66
I 5 RRMS f 32 32 3.0 None 2.5 None 81
I 6 RRMS f 29 29 4.5 IFN 4.0 IFN 91
I 7 RRMS f 24 24 2.0 None 1.5 None 51
I 8 RRMS f 32 32 4.0 None 2.0 None 72
I 9 SPMS f 25 20 4.0 FM 4.5 None 91
II 10 RRMS f 22 21 2.0 IFN 2.0 NA 73
II 11 RRMS f 47 47 3.5 None 2.0 IFN 72
II 12 RRMS f 34 31 4.0 None 3.0 IFN 79
II 13§ RRMS f 59 40 6.0 None / / /
II 14 SPMS m 36 32 6.0 Mitox 5.0 Mitox 92
II 15 SPMS f 53 50 5.5 None 5.5 None 93
III 16 RRMS f 32 32 2.0 None 2.0 IFN 73
III 17 RRMS f 49 38 6.0 None 6.0 FM 91
III 18 SPMS m 52 37 5.5 None 5.5 None 80
III 19§ RRMS f 38 23 6.5 None / / /
III 20 RRMS f 48 47 4.0 IFN 3.5 IFN 91
III 21 SPMS m 52 41 2.5 GA 2.5 FM 51
III 22 SPMS f 54 35 7.5 None 7.0 None 92
III 23 RRMS m 40 40 2.0 None 2.0 IFN 72
III 24 RRMS m 61 61 2.0 None 4.0 IFN 91
III 25 RRMS f 31 30 2.0 IFN 1.0 IFN 38
III 26 RRMS f 21 21 3.5 None 1.0 IFN 37
III 27 RRMS f 18 18 6.0 None 1.5 None 51
III 28 RRMS f 45 45 2.0 None 2.0 None 72
III 29 RRMS m 52 27 4.5 None 4.5 None 66
III 30 RRMS f 43 43 6.0 FA 6.0 FA 94
  1. EDSS = Expanded Disability Status Scale; FA = fumaric acid; FM = fingolimod; GA = glatiramer acetate; IFN = interferon-β; Mitox = mitoxantrone; NA = natalizumab; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.
  2. *Scores on the EDSS range from 0 to 10, with higher scores indicating a greater degree of disability.
  3. MS severity refers to the percentile rank of each individual study patient compared to a matched MS cohort of the MSBase Registry. Values were determined using MS Curves[18].
  4. §These patients were lost to follow-up.